Atezolizumab Improves Overall Survival in Non-Small Cell Lung Cancer

In patients with previously treated non-small cell lung cancer (NSCLC), atezolizumab increases overall survival compared with docetaxel, regardless of programmed death ligand 1 (PD-L1) status, histology, and subsequent immunotherapy, according to a new study published in the Journal of Thoracic Oncology. "In clinical trials conducted with immunotherapy, the benefit to patients is usually sustained over time," write the investigators, led by first author Julien Mazieres, MD, PhD, Professor of Res...
Continue reading

Esophageal-Sparing Radiotherapy Reduces Toxicity in Non-Small Cell Lung Cancer

In patients with advanced non-small cell lung cancer (NSCLC), esophageal-sparing intensity-modulated radiotherapy (ES-IMRT) decreased the incidence of treatment-related esophagitis and demonstrated a trend toward improved esophageal quality of life compared with standard radiotherapy (RT), according to results recently presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting. While commonly used to alleviate local symptoms in patients with advanced NSCLC, palliative thorac...
Continue reading

Expert Guidance on the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer With Mark G. Kris, MD and Nathan Pennell, MD

 One of the two major subtypes of lung cancer, non-small cell lung cancer (NSCLC) is a challenging disease to treat, with most patients being diagnosed at a locally advanced or metastatic stage. Despite the use of tumor histology and relevant molecular biomarkers to determine treatment strategies, outcomes remain poor, with a 5-year survival rate of only 24%. In this episode of Oncology Data Advisor, Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Ketter...
Continue reading

Atezolizumab Combo Effective in EGFR-Mutated Non-Small Cell Lung Cancer

The addition of atezolizumab to bevacizumab/carboplatin/paclitaxel (BCP) significantly prolongs overall survival in patients with non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, according to results of a final efficacy analysis presented this week at the European Medical Society for Oncology (ESMO) Virtual Congress 2020. "Atezolizumab inhibits programmed death-ligand 1 (PD-L1) to restore anti-cancer immunity; bevacizumab may enhance atezoli...
Continue reading

Brigatinib More Effective Than Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

A second interim analysis of the phase 3 ALTA-1L trial shows that brigatinib demonstrates superior results in patients with advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer (NSCLC) compared with crizotinib. Crizotinib is not the most effective therapy for patients with ALK-positive NSCLC, as disease progression occurs frequently in the central nervous system, possibly due to poor drug penetration. In previous phase 1/2 trials, brigatinib, a next-generation ALK inhibitor with ...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.